TY  - JOUR
AU  - Rugo, H S
AU  - O'Shaughnessy, J
AU  - Boyle, F
AU  - Toi, M
AU  - Broom, R
AU  - Blancas, I
AU  - Gumus, M
AU  - Yamashita, T
AU  - Im, Y-H
AU  - Rastogi, P
AU  - Zagouri, F
AU  - Song, C
AU  - Campone, M
AU  - San Antonio, B
AU  - Shahir, A
AU  - Hulstijn, M
AU  - Brown, J
AU  - Zimmermann, A
AU  - Wei, R
AU  - Johnston, S R D
AU  - Reinisch, M
AU  - Tolaney, S M
AU  - monarchE Committee Members
PY  - 2022
DO  - 10.1016/j.annonc.2022.03.006
UR  - http://hdl.handle.net/10668/21896
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk, early breast cancer (EBC) demonstrated a clinically meaningful improvement in invasive...
LA  - en
KW  - HER2 negative
KW  - HR positive
KW  - abemaciclib
KW  - early breast cancer
KW  - monarchE
KW  - safety
KW  - Aminopyridines
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Benzimidazoles
KW  - Breast Neoplasms
KW  - Diarrhea
KW  - Female
KW  - Humans
KW  - Neoplasm Recurrence, Local
KW  - Patient Reported Outcome Measures
KW  - Quality of Life
KW  - Receptor, ErbB-2
TI  - Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
TY  - research article
VL  - 33
ER  -